Sales of Iclusig, a drug used primarily in the treatment of chronic myeloid leukemia, were recently suspended in a joint decision between the FDA and Ariad Pharmaceuticals, the manufacturer of Iclusig. Iclusig gained FDA approval less than a year ago, in December, 2012. At the time the drug was approved—under an accelerated process –clinical trials had demonstrated a higher-than-normal risk of cardiovascular events among those taking Iclusig. This risk required Ariad to include a boxed warning alerting patients and physicians to the risks of blood clots and liver toxicity in patients taking Iclusig.